Michel Gréco
Chairman at Centre Hospitalier Saint Joseph - Saint Luc
Michel Gréco active positions
Companies | Position | Start | End |
---|---|---|---|
Texcell SA
Texcell SA Pharmaceuticals: MajorHealth Technology Texcell SA is a contract research organization that provides services for viral clearances, viral safety testing, and the manufacture of GMP cell banks to pharmaceutical companies and bioventures. The private company is based in France and has subsidiaries in various locations, including the United States. The French company has offices and laboratories in various locations around the world, including France, the United States, and Japan. The company's capabilities include in vivo, in vitro, toxicology, immunotoxicity, and immunogenicity testing, as well as CGMP cell banking and preparation of fully characterized virus stocks. Texcell has recently strengthened its activities to face the growing demand for tests related to COVID-19. The company is developing new innovative tests and new protocols in molecular biology and immunology. | Director/Board Member | 24/05/2010 | - |
Noraker SARL
Noraker SARL Medical SpecialtiesHealth Technology Noraker SARL designs, produces and markets synthetic and absorbable biomaterial-based implantable medical devices. It offers dental surgery and orthopedic products. The firm's services include filling bone defects such as cyst and dental granuloma. The company was founded by Rachid Zenati in 2005 and is headquartered in Villeurbanne, France. | Chairman | 18/05/2011 | - |
Centre Hospitalier Saint Joseph - Saint Luc | Chairman | - | - |
Hopital de Fourvière | Director/Board Member | - | - |
Career history of Michel Gréco
Former positions of Michel Gréco
Companies | Position | Start | End |
---|---|---|---|
VALNEVA | Director/Board Member | 12/12/2012 | 30/06/2016 |
Independent Dir/Board Member | 12/12/2012 | 30/06/2016 | |
Immutep SAS
Immutep SAS Pharmaceuticals: MajorHealth Technology Immutep SAS specializes in biotechnology research and development. It develops immunotherapy treatments for cancer and autoimmune diseases. The company was founded by Frédéric Triebel on October 17, 2001 and is headquartered Orsay, France. | Director/Board Member | 24/05/2010 | 18/11/2015 |
GlycoVaxyn AG
GlycoVaxyn AG BiotechnologyHealth Technology GlycoVaxyn AG developed and produced bioconjugate vaccines. The company was founded in 2004 and was headquartered in Schlieren, Switzerland. | Chairman | - | 30/06/2013 |
Intercell AG
Intercell AG Pharmaceuticals: MajorHealth Technology Intercell AG engages in the research, development, manufacture, and marketing of novel vaccines for the prevention and treatment of infectious diseases. Its products include Japanese encephalitis vaccine, Pseudomonas vaccine, Clostridium difficile vaccine, tuberculosis vaccine, and pandemic influenza vaccine patch. Its technology platforms involve patch-based delivery system and proprietary human monoclonal antibody discovery system. The company was founded by Alexander von Gabain, Max Birnstiel, Michael Buschle, Walter Schmidt, and Aaron Hirsh on December 3, 1997 and is headquartered in Vienna, Austria. | Director/Board Member | 02/01/2012 | 28/05/2013 |
Independent Dir/Board Member | 01/07/2003 | 28/05/2013 | |
Vivalis SA
Vivalis SA Pharmaceuticals: OtherHealth Technology Vivalis SA manufactures human and animal vaccines. The firm specializes in the research and development of vaccines and antiviral molecules, as well as in recombinant therapeutic protein and monoclonal antibody expression systems development. The firm's embryonic stem cells are used for practical applications in human and animal health. It also helps its clients in a case by case basis for the development of processes in the frame of service agreement. The company was founded in April 1999 and is headquartered in France. | Director/Board Member | 05/05/2010 | 28/05/2013 |
░░░░░░░░░░░░░ ░░░░ ░░░░░░░ ░░░░░░░░░░░ ░░░░ | ░░░░░░░░░░░░░░ ░░░░░░ | ░░░░░░░░░░ | ░░░░░░░░░░ |
░░░░░ ░░░░░░ ░░ ░░░░░░░ ░░░░░░░░░░ | ░░░░░░░░░░░░░░ ░░░░░░ | ░░░░░░░░░░ | ░░░░░░░░░░ |
░░░░░ ░░░░░░░░░░░░░ ░░░░ | ░░░░░░░░░░░░░░ ░░░░░░ | ░░░░░░░░░░ | - |
░░░░░░░░░ ░░░░░░░░ ░░░ | ░░░░░░░░░░░░░░ ░░░░░░ | - | ░░░░░░░░░░ |
░░░░░░░ ░░░░ | ░░░░░░░░░░░░░░ ░░░░░░ | ░░░░░░░░░░ | ░░░░░░░░░░ |
░░░░░░░ ░░░░░░░ ░░░ ░░░░ | ░░░░░░░░░ | ░░░░░░░░░░ | ░░░░░░░░░░ |
░░░░░░ ░░░░░ ░░ | ░░░░░░░ | ░░░░░░░░░░ | - |
░░░░░░░░░ ░░░ | ░░░░░░░░░░░░░░ ░░░░░░ | - | - |
░░░░░░░░ ░░░░░░░░ ░░░░░ ░░░░░░ | ░░░░░░░░░ ░░░░░░░░░░░░░░░░░ | ░░░░░░░░░░ | - |
░░░░░░░░░░ ░░░░░░░░░░░░ ░░ | ░░░░░░░░░░░░░░ ░░░░░░ | - | - |
░░░░░░░░ ░░ ░░░░░░░░░ ░░░░░░░░░░░░ ░░ ░░░░ | ░░░░░░░░░░░░░░ ░░░░░░ | - | - |
░░░░░░░░░ ░░░░░░░░░░░░░░░░░ | - | - | |
░░░░░░░░ ░░░░░░░ ░░░░░░░░░░░░░ | ░░░░░░░░░ | - | - |
░░░░░░░░░░░░░ ░░░░░░░░░░ ░░ ░░░░░░░░░░░░░░ ░░░░░░░░░░░░░ | ░░░░░░░░░ ░░░░░░░░░░░░░░░░░ | - | - |
░░░░░░ ░░░░░░░ | ░░░░░░░░░ | - | - |
░░░░░░░░░░ ░░░░░░░░░░░░░░░ ░░░ | ░░░░░░░░░░░░░░ ░░░░░░ | ░░░░░░░░░░ | - |
░░░░░░ ░░░░░░░░░░░░░ ░░░░ | ░░░░░░░░░░░░░░ ░░░░░░ | ░░░░░░░░░░ | - |
░░ ░░░░░░░░░░ ░░░░░ | ░░░░░░░░░░░░░░ ░░░░░░ | ░░░░░░░░░░ | - |
Training of Michel Gréco
Sciences Po | Undergraduate Degree |
University of Western Ontario | Masters Business Admin |
Statistics
International
France | 15 |
United States | 5 |
Switzerland | 3 |
Operational
Director/Board Member | 17 |
Corporate Officer/Principal | 3 |
Chairman | 3 |
Sectoral
Health Technology | 17 |
Consumer Services | 4 |
Commercial Services | 3 |
Positions held
Active
Inactive
Listed companies
Private companies
Linked companies
Listed companies | 1 |
---|---|
VALNEVA | Health Technology |
Private companies | 24 |
---|---|
VaxGen, Inc.
VaxGen, Inc. BiotechnologyHealth Technology VaxGen, Inc. is a biopharmaceutical company, owns a state-of-the-art biopharmaceutical manufacturing facility that can be used to make cell culture or microbial biologic products. The company has ended all product development activities and sold or otherwise terminated its drug development programs. It is seeking to maximize the value of its remaining tangible and intangible assets through a transaction or series of transactions, including the sale of the manufacturing facility. The company was founded on November 01, 1995 and is headquartered in South San Francisco, CA. | Health Technology |
Texcell SA
Texcell SA Pharmaceuticals: MajorHealth Technology Texcell SA is a contract research organization that provides services for viral clearances, viral safety testing, and the manufacture of GMP cell banks to pharmaceutical companies and bioventures. The private company is based in France and has subsidiaries in various locations, including the United States. The French company has offices and laboratories in various locations around the world, including France, the United States, and Japan. The company's capabilities include in vivo, in vitro, toxicology, immunotoxicity, and immunogenicity testing, as well as CGMP cell banking and preparation of fully characterized virus stocks. Texcell has recently strengthened its activities to face the growing demand for tests related to COVID-19. The company is developing new innovative tests and new protocols in molecular biology and immunology. | Health Technology |
DrugAbuse Sciences SAS
DrugAbuse Sciences SAS Pharmaceuticals: MajorHealth Technology DrugAbuse Sciences SAS develops therapies for treatment of alcohol abuse and opiate addiction. It also operates an educational website which is designed to provide clinicians, patients access to information and services related to alcohol abuse treatment and care. The company is headquartered in Lyon, France | Health Technology |
Institut Mérieux Human Health | |
Powderject Technologies BV | |
GlycoVaxyn AG
GlycoVaxyn AG BiotechnologyHealth Technology GlycoVaxyn AG developed and produced bioconjugate vaccines. The company was founded in 2004 and was headquartered in Schlieren, Switzerland. | Health Technology |
European Vaccine Manufacturers | |
International Federation of Pharmaceutical Manufacturers
International Federation of Pharmaceutical Manufacturers BiotechnologyHealth Technology The International Federation of Pharmaceutical Manufacturers and Traders is a global organization that promotes technology transfer in the pharmaceutical industry. The non-profit company is based in Geneva, Switzerland. The Swiss company believes that technology transfer helps bridge research and development gaps, increases the availability of vaccines and medicines, and stimulates investment in key industrial areas. David Reddy has been the CEO of the company since 2024. | Health Technology |
Pasteur Merieux MSD Ltd. | |
Sanofi Pasteur
Sanofi Pasteur BiotechnologyHealth Technology Sanofi Pasteur SA develops, manufactures and supplies vaccines. It provides vaccines for bacterial and viral diseases, including diphtheria, typhoid fever, and poliomyelitis. The company was founded in 1990 and is headquartered in Lyon, France. | Health Technology |
Vivalis SA
Vivalis SA Pharmaceuticals: OtherHealth Technology Vivalis SA manufactures human and animal vaccines. The firm specializes in the research and development of vaccines and antiviral molecules, as well as in recombinant therapeutic protein and monoclonal antibody expression systems development. The firm's embryonic stem cells are used for practical applications in human and animal health. It also helps its clients in a case by case basis for the development of processes in the frame of service agreement. The company was founded in April 1999 and is headquartered in France. | Health Technology |
Intercell AG
Intercell AG Pharmaceuticals: MajorHealth Technology Intercell AG engages in the research, development, manufacture, and marketing of novel vaccines for the prevention and treatment of infectious diseases. Its products include Japanese encephalitis vaccine, Pseudomonas vaccine, Clostridium difficile vaccine, tuberculosis vaccine, and pandemic influenza vaccine patch. Its technology platforms involve patch-based delivery system and proprietary human monoclonal antibody discovery system. The company was founded by Alexander von Gabain, Max Birnstiel, Michael Buschle, Walter Schmidt, and Aaron Hirsh on December 3, 1997 and is headquartered in Vienna, Austria. | Health Technology |
Immutep SAS
Immutep SAS Pharmaceuticals: MajorHealth Technology Immutep SAS specializes in biotechnology research and development. It develops immunotherapy treatments for cancer and autoimmune diseases. The company was founded by Frédéric Triebel on October 17, 2001 and is headquartered Orsay, France. | Health Technology |
ID Biomedical Corp.
ID Biomedical Corp. Medical SpecialtiesHealth Technology ID Biomedical Corp. develops gene-based disease testing and subunit vaccines. It conducts research, development, manufacturing, sales, and marketing from its facilities in Canada and in the United States. The company was founded in 1991 and is headquartered in Vancouver, Canada. | Health Technology |
Noraker SARL
Noraker SARL Medical SpecialtiesHealth Technology Noraker SARL designs, produces and markets synthetic and absorbable biomaterial-based implantable medical devices. It offers dental surgery and orthopedic products. The firm's services include filling bone defects such as cyst and dental granuloma. The company was founded by Rachid Zenati in 2005 and is headquartered in Villeurbanne, France. | Health Technology |
Flamel Technologies, Inc. | |
Powderject Pharmaceuticals Plc
Powderject Pharmaceuticals Plc Medical SpecialtiesHealth Technology Powderject Pharmaceuticals Plc develops pharmaceutical products. It offers researching, developing, manufacturing and marketing for existing and next generation vaccines. The company was founded in 1993 and is located in Oxford, UK | Health Technology |
Argos Therapeutics, Inc.
Argos Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Argos Therapeutics, Inc. was a biopharmaceutical company. It engages in development and commercialization of individualized immunotherapies for the treatment of cancer and infectious diseases based on its proprietary technology platform called Arcelis. The firm's product include AGS-003 for the treatment of metastatic renal cell carcinoma, and other cancers; and AGS-004 for the treatment of human immunodeficiency virus. The company was founded by Bruce A. Sullenger, Eli Gilboa, John A. Irick and Ralph M. Steinman on May 8, 1997 and was headquartered in Durham, NC. | Health Technology |
Aeras Global TB Vaccine Foundation
Aeras Global TB Vaccine Foundation Miscellaneous Commercial ServicesCommercial Services Aeras Global TB Vaccine Foundation is a non-profit organization, which engages in the development of tuberculosis vaccines in partnership with other biotech, pharmaceutical, and academic organizations. Its product pipeline includes AdS Ag85A, MTBCAV, VPM 1002, and RUTI. The company is headquartered in Rockville, MD. | Commercial Services |
International AIDS Vaccine Initiative, Inc.
International AIDS Vaccine Initiative, Inc. Pharmaceuticals: MajorHealth Technology International AIDS Vaccine Initiative, Inc. researches and develops to prevent HIV infection and AIDS. It researches and develops vaccine candidates, conducts policy analyses, and serves as an advocate for the field with offices in Africa, India, and Europe. The firm's HIV research and development focuses on three strategies: the design of vaccine immunogens capable of inducing specialized proteins known as broadly neutralizing antibodies, the optimization and development of these antibodies as prevention products, and the development of replicating viral vectors and mRNA. The company was founded in 1996 by Seth Berkley and Lee C. Smith and is headquartered in New York, NY. | Health Technology |
Centre Hospitalier Saint Joseph - Saint Luc | |
Hopital de Fourvière | |
Synthelis SAS
Synthelis SAS Pharmaceuticals: MajorHealth Technology Synthelis SAS manufactures membrane proteins. It specializes in the production, purification, and characterization of custom membrane proteins. The firm's services Membrane Protein (MP) expression, proteoliposomes, MP in detergents, feasibility study, and quality controls. Synthelis' technology enables the embedding of membrane proteins in liposomes directly during the translation step, allowing the production of active ready-to-use proteoliposomes. The company was founded by Bruno Tillier and Jean-Luc Lenormand in January 2011 and is headquartered in La Tronche, France. | Health Technology |
Michel Greco SA
Michel Greco SA Miscellaneous Commercial ServicesCommercial Services Michel Greco SA provides postal, courier, and express services. The private company is based in Luxembourg, Luxembourg. The Luxembourger company was founded in 1987 by Michel Gréco. | Commercial Services |
- Stock Market
- Insiders
- Michel Gréco
- Experience